Residency · Residency · Child Adolescent Psychiatry

Pharmacotherapy for Pediatric Insomnia and Sleep Disorders

Introduction

Sleep disturbances are among the most common complaints in child and adolescent psychiatry, affecting 25-40% of children and adolescents at some point in development. While behavioral interventions are first-line, pharmacotherapy is frequently employed despite a limited evidence base and few FDA-approved options for pediatric insomnia. Understanding normal sleep physiology, diagnostic categories, and the benefits and risks of pharmacological agents is essential for safe and effective practice.

Normal Sleep Development

Total sleep needs decrease from fourteen to seventeen hours in newborns to eight to ten hours in adolescents. Circadian rhythm maturation occurs across childhood, with a natural phase delay emerging during puberty that biologically shifts the preferred sleep-wake schedule later. Sleep architecture changes significantly: the proportion of REM sleep decreases from 50% in newborns to 20-25% in adolescents. Slow-wave sleep is most abundant in prepubertal children and declines during adolescence. Melatonin secretion patterns are influenced by light exposure, puberty, and individual chronotype.

Classification of Pediatric Sleep Disorders

Behavioral Insomnia of Childhood

Behavioral insomnia of childhood comes in two main forms. The sleep-onset association type describes situations where the child requires specific conditions to fall asleep, such as parental presence, rocking, or feeding. The limit-setting type occurs when the caregiver fails to establish or enforce appropriate bedtime rules. The combined type is most common in clinical practice. Behavioral interventions are the definitive treatment for both forms.

Delayed Sleep-Wake Phase Disorder

This disorder is prevalent in adolescents due to the biological circadian phase delay that accompanies puberty. Affected adolescents have difficulty falling asleep before 11 PM to 2 AM and consequently have difficulty waking for school. The condition is often mislabeled as insomnia when it is fundamentally a circadian rhythm issue. Evening light exposure, particularly from screens and LED lighting, exacerbates the problem.

Insomnia Comorbid with Psychiatric Disorders

Anxiety disorders cause difficulty falling asleep through worry, rumination, and hyperarousal. ADHD is associated with both intrinsic sleep-onset delay and stimulant-related insomnia. Depression may present with either insomnia or hypersomnia as a core symptom. ASD is associated with well-documented melatonin deficiency and circadian disruption. PTSD causes nightmares, hyperarousal, and fragmented sleep.

Parasomnias

Non-REM parasomnias, including sleepwalking, sleep terrors, and confusional arousals, are common in school-age children. REM-related parasomnias include nightmare disorder. Most non-REM parasomnias are self-limited and require safety measures rather than pharmacotherapy.

Non-Pharmacological Interventions (First-Line)

Behavioral interventions form the foundation of pediatric insomnia treatment. Sleep hygiene education covers maintaining a consistent bedtime routine, ensuring a cool and dark sleep environment, and enforcing a screen-free period before bed. Graduated extinction and positive bedtime routines are effective for behavioral insomnia. Stimulus control principles dictate that the bed should be used only for sleep and that the child should leave bed if unable to fall asleep after twenty minutes. Sleep restriction therapy limits time in bed to match actual sleep time, then gradually extends it as sleep efficiency improves. Chronotherapy and bright light therapy address delayed sleep phase. CBT for insomnia adapted for adolescents has strong evidence supporting its effectiveness.

Pharmacotherapy

Melatonin

Melatonin is the most commonly used pharmacological agent for pediatric insomnia. In the United States, it is not FDA-regulated as a medication but rather classified as a dietary supplement, which means quality and dosing accuracy vary among products. It works by binding MT1 and MT2 receptors in the suprachiasmatic nucleus, promoting circadian entrainment. It is particularly effective for reducing sleep-onset latency in children with ASD and ADHD. Dosing ranges from 0.5 to 5 mg administered thirty to sixty minutes before the desired bedtime, and lower doses of 0.5-1 mg are often as effective as higher doses. Prolonged-release melatonin has been approved in Europe for neurodevelopmental disorders. Side effects are generally mild and include morning grogginess, headache, and vivid dreams. Long-term safety data in children are reassuring but still accumulating, and concerns about effects on pubertal development remain theoretical.

Alpha-2 Agonists

Clonidine is widely used off-label for sleep initiation, particularly in children with ADHD and ASD, at doses of 0.05-0.2 mg at bedtime. It promotes sleep through central alpha-2 adrenergic agonism, reducing noradrenergic arousal. It is particularly useful for stimulant-associated insomnia in ADHD. Side effects include hypotension, bradycardia, rebound hypertension with abrupt discontinuation, and morning sedation. Guanfacine extended-release is less sedating and may be more helpful for sleep maintenance.

Antihistamines

Diphenhydramine and hydroxyzine are commonly used for pediatric insomnia through H1 receptor antagonism causing sedation. However, rapid tolerance develops, which limits their long-term efficacy. Side effects include anticholinergic effects such as dry mouth, constipation, and urinary retention, paradoxical excitation in young children, and next-day sedation. They are not recommended for chronic use.

Trazodone

Low-dose trazodone at 25-100 mg is frequently prescribed off-label for insomnia in adolescents. Its mechanism involves 5-HT2A antagonism, H1 antagonism, and weak serotonin reuptake inhibition. Pediatric randomized controlled trial data for insomnia are limited. Side effects include morning sedation, orthostatic hypotension, and priapism, which is rare but serious. It may be particularly useful when insomnia co-occurs with depression or anxiety.

Benzodiazepines and Z-Drugs

These agents are generally not recommended for routine pediatric insomnia. They carry risks of tolerance, dependence, rebound insomnia, and paradoxical reactions. Z-drugs such as zolpidem and eszopiclone have minimal pediatric safety data. They may have a limited role in specific circumstances, such as acute anxiety-related insomnia in adolescents, but only with short-term use.

Dual Orexin Receptor Antagonists (DORAs)

Suvorexant and similar agents block orexin/hypocretin receptors to reduce wakefulness signaling. They are FDA-approved for adult insomnia but have no pediatric FDA approval. There is emerging interest in pediatric use, but the evidence is insufficient to recommend routine use. Side effects include sleep paralysis, hypnagogic hallucinations, and next-day somnolence.

Special Populations

ADHD and Stimulant-Related Insomnia

When an ADHD patient presents with insomnia, clinicians should first determine whether the insomnia is intrinsic to the ADHD or medication-induced. Strategies include adjusting stimulant timing, switching to a shorter-acting formulation, or adding melatonin or clonidine at bedtime. Simply adding sedating medications without addressing the root cause should be avoided.

Autism Spectrum Disorder

Sleep problems affect 50-80% of children with ASD. Melatonin has the strongest evidence base in this population. Behavioral interventions should be adapted to the child's developmental level. Sensory sensitivities in the sleep environment, such as sensitivity to textures, sounds, or lighting, should be addressed.

Mood Disorders

Treating the underlying mood disorder is the priority, as insomnia often resolves with effective antidepressant or mood stabilizer treatment. Benzodiazepines should be avoided in the context of bipolar disorder due to the risk of disinhibition. Medications with inherent sleep-promoting properties, such as mirtazapine or quetiapine, may be considered as the primary treatment when insomnia is a prominent feature.

Clinical Pearls

Behavioral interventions are the foundation of pediatric insomnia treatment and should be implemented before or alongside any pharmacological agent. Melatonin is effective for reducing sleep-onset latency, but the quality and dosing accuracy of over-the-counter preparations vary widely; recommending reputable brands with USP verification is prudent. Clonidine is useful for stimulant-related insomnia in ADHD but requires monitoring for cardiovascular effects and must never be stopped abruptly due to the risk of rebound hypertension. Chronic use of sedating antihistamines for pediatric insomnia is not evidence-based and should be discouraged because of tolerance development and anticholinergic burden.

References

1. Owens, J. A., & Mindell, J. A. (2011). Pediatric insomnia. Pediatric Clinics of North America, 58(3), 555-569.
2. Malow, B. A., Findling, R. L., Engel, J. M., et al. (2012). A practice pathway for the identification, evaluation, and management of insomnia in children and adolescents with autism spectrum disorders. Pediatrics, 130(Supplement 2), S106-S124.
3. Bruni, O., Alonso-Alconada, D., Besag, F., et al. (2015). Current role of melatonin in pediatric neurology: clinical recommendations. European Journal of Paediatric Neurology, 19(2), 122-133.
4. Mindell, J. A., Kuhn, B., Lewin, D. S., et al. (2006). Behavioral treatment of bedtime problems and night wakings in infants and young children. Sleep, 29(10), 1263-1276.

Read this lecture as Markdown